interferon - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.95 [0.02, 50.33]< 10%1 study (1/-)51.0 %some concernnot evaluable moderatecrucial-
deaths 0.65 [0.34, 1.24]< 131%7 studies (7/-)90.4 %some concernserious moderatecrucial-
clinical deterioration 0.50 [0.18, 1.38]< 10%1 study (1/-)90.9 %some concernnot evaluable moderateimportant-
clinical improvement 2.34 [1.35, 4.05]> 10%2 studies (2/-)99.9 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 8.77 [0.94, 81.67]> 10%1 study (1/-)97.1 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 3.15 [1.39, 7.14]> 10%1 study (1/-)99.7 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 2.17 [1.34, 3.51]> 10%3 studies (3/-)99.9 %some concernnot evaluable moderateimportant-
death or ventilation 0.83 [0.35, 1.93]< 146%2 studies (2/-)67.1 %some concernnot evaluable moderateimportant-
hospital discharge 1.97 [0.84, 4.60]> 10%2 studies (2/-)94.1 %some concernnot evaluable moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.75 [0.34, 1.69]< 10%3 studies (3/-)75.5 %some concernnot evaluable moderateimportant-
viral clearance 1.08 [0.43, 2.74]> 149%2 studies (2/-)56.8 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 10%1 study (1/-)13.7 %some concernnot evaluable moderateimportant-
viral clearance by day 14 10.23 [1.12, 93.35]> 10%1 study (1/-)98.0 %some concernnot evaluable moderateimportant-
viral clearance by day 7 2.33 [0.55, 9.83]> 10%1 study (1/-)87.5 %some concernnot evaluable moderateimportant-
ICU admission 0.49 [0.24, 1.00]< 10%3 studies (3/-)97.4 %some concernnot evaluable moderatenon important-
recovery 2.19 [1.03, 4.67]> 10%1 study (1/-)97.9 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.99 [0.17, 5.88]< 10%2 studies (2/-)50.5 %some concernnot evaluable moderateimportant-
superinfection 0.18 [0.02, 1.59]< 10%1 study (1/-)93.8 %some concernnot evaluable moderateimportant-
adverse events 1.41 [0.74, 2.67]< 10%2 studies (2/-)14.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.